NCT06161844View on ClinicalTrials.gov

Efficacy and Safety of Semaglutide Injection (HD1916) in Patients With Type 2 Diabetes Mellitus

PHASE3CompletedINTERVENTIONAL
Enrollment

506

Participants

Timeline

Start Date

February 23, 2024

Primary Completion Date

May 14, 2025

Study Completion Date

May 14, 2025

Conditions
Type 2 Diabetes Mellitus
Interventions
DRUG

semaglutide injection (HD1916)

Up to 1.0 mg semaglutide injected subcutaneously once-weekly for 32 weeks Other Name: HD1916

DRUG

Ozempic®

Up to 1.0 mg semaglutide injected subcutaneously once-weekly for 32 weeks Other Name: Ozempic Injectable Product

Trial Locations (1)

510235

Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangdong

All Listed Sponsors
lead

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

INDUSTRY

NCT06161844 - Efficacy and Safety of Semaglutide Injection (HD1916) in Patients With Type 2 Diabetes Mellitus | Biotech Hunter | Biotech Hunter